Therapeutic Solutions International Inc (OP: TSOI )

0.0076 USD -0.0004 (-5.00%)

Official Closing Price Updated: 3:52 PM EST, Jan 15, 2021 Add to My Watchlist

Price and Volume

Volume	5,445,500
Open	0.0083
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0080
Today's Range	0.0076 - 0.0085
52wk Range	0.0008 - 0.0230
Shares Outstanding	800,165,450
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences

January 13, 2021

Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls

Therapeutic Solutions International Reports QuadraMune™ Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity

January 05, 2021

Company Continues Elucidation of Immunological Mechanisms of QuadraMune™ Nutraceutical Currently in Clinical Trials for COVID-19 Prevention

Performance

YTD	+18.75%	+18.75%
1 Month	+13.43%	+13.43%
3 Month	-1.30%	-1.30%
6 Month	+11.76%	+11.76%
1 Year	+230.43%	+230.43%

More News

Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company

December 31, 2020

Therapeutic Solutions International Reports QuadraMune™ Increases T Cell Immunity in Animal Studies

December 30, 2020

Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction

December 21, 2020

Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention

December 16, 2020

Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder

December 09, 2020

Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction

December 02, 2020

Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data

December 01, 2020

QuadraMune™ Synergizes with Metformin to Stimulate Anti-Viral Defenses in Pilot Clinical Trial

November 24, 2020

Therapeutic Solutions International Appoints Famela Ramos as Vice President, Business Development

November 16, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.